Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification Criteria for Acute Retinal Necrosis Syndrome. Am J Ophthalmol. 228:237-244.
Hillenkamp J, Nölle B, Bruns C, Rautenberg P, Fickenscher H, Roider J (2009) Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 116(10):1971–5. e2
Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya P, Yeh S, Bakri SJ, Ehlers JP (2017) Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. Ophthalmology. 124(3):382–92
Menghini M, Raja V, Raiter J, Balaratnasingam C, Constable IJ (2021) Acute retinal necrosis associated with herpes zoster vaccination. Retin Cases Brief Rep. 15(2):166–8
Heath G, Depledge DP, Brown JR, Hale AD, Tutil H, Williams R, Breuer J (2017) Acute Retinal Necrosis Caused by the Zoster Vaccine Virus. Clin Infect Dis. 65(12):2122–5
Ali A, Kirschenbaum MD, Sharma S, Wandel TL (2021) Acute retinal necrosis and contralateral cutaneous eruption after the shingles vaccine. Retin Cases Brief Rep. 15(1):43–4
Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 3(4):109–20
Van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B (2021) A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 17(6):1714–32
Bharucha T, Ming D, Breuer J (2017) A critical appraisal of “Shingrix”, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 13(8):1789–97
Heineman TC, Cunningham A, Levin M (2019) Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 59:42–8
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group (2016). Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 375(11):1019-32.
Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, Ramsay M (2018) Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 3(2):e82-90
Langan SM, Smeeth L, Margolis DJ, Thomas SL (2013) Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 10(4):e1001420
Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ (2016) Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. J Infect Dis. 213(12):1872–5
Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR (2021) Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin Infect Dis. 73(6):949–56
Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, MaCurdy TE, Kelman J, Dooling K (2021) Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin Infect Dis. 73(6):941–8
Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV (2019) Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) – United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep. 68(4):91–4
Food and Drug Administration. briefing document FDA: Shingrix (zoster vaccine recombinant, adjuvanted). Presented at the Vaccines and Related Biological Products Advisory Committee meeting, Silver Spring, MD; September 13, 2017. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM575190.pdf
Summary of product characteristics: Shingrix: European Medicines Agency. 2020 [ updated 2020 Sep 28; cited 2020 Oct 2]. https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_en.pdf
Invernizzi A, Agarwal AK, Ravera V, Mapelli C, Riva A, Staurenghi G, McCluskey PJ, Viola F (2018) Comparing optical coherence tomography findings in different aetiologies of infectious necrotising retinitis. Br J Ophthalmol. 102(4):433–7
Invernizzi A, Agarwal A, Ravera V, Oldani M, Staurenghi G, Viola F (2018) Optical coherence tomography findings in cytomegalovirus retinitis: A Longitudinal Study. Retina. 38(1):108–17
Cheng JY, Margo CE (2022) Ocular adverse events following vaccination: overview and update. Surv Ophthalmol. 67(2):293–306
Zou Y, Kamoi K, Zong Y, Zhang J, Yang M, Ohno-Matsui K (2023) Ocular Inflammation Post-Vaccination. Vaccines (Basel). 11(10):1626
Ichhpujani P, Parmar UPS, Duggal S, Kumar S (2022) COVID-19 Vaccine-Associated Ocular Adverse Effects: An Overview. Vaccines (Basel). 10(11):1879
Lu TJ, Ta CN (2022) Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine. Case Rep Ophthalmol. 13(1):104–8
Chen RI, Deaner JD, Srivastava SK, Lowder CY (2020) Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine. Am J Ophthalmol Case Rep. 8(20):100962
Wenkel H, Rummelt C, Rummelt V, Jahn G, Fleckenstein B, Naumann GO (1993) Detection of varicella zoster virus DNA and viral antigen in human cornea after herpes zoster ophthalmicus. Cornea. 12(2):131–7
Mehta SK, Nelman-Gonzalez M, Tyring SK, Tong Y, Beitman A, Crucian BE, Renner AN, Pierson DL (2017) Localization of VZV in saliva of zoster patients. J Med Virol. 89(9):1686–9
Hojjatie SL, Shantha JG, O’Keefe GD, Kraft CS, Voloschin A, Grossniklaus H, Yeh S (2022) Cytopathology of Vitreous Specimens in Acute Retinal Necrosis. Ocul Immunol Inflamm. 30(7–8):1609–16
Kimura H, Wang Y, Pesnicak L, Cohen JI, Hooks JJ, Straus SE, Williams RK (1998) Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. J Infect Dis. 178(2):310–7
Lehmann A, Matoba A (2018) Reactivation of Herpes Zoster Stromal Keratitis After HZ/su Adjuvanted Herpes Zoster Subunit Vaccine. Ophthalmology. 125(11):1682
Heydari-Kamjani M, Vante I, Uppal P, Demory Beckler M, Kesselman MM (2019) Uveitis Sarcoidosis Presumably Initiated After Administration of Shingrix Vaccine. Cureus. 11(6):3278–88
Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR (1994) Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci. 35(8):3278–88
Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M (2010) IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 10(4):251-61.
Urban B, Bakunowicz-Łazarczyk A, Michalczuk M (2014) Immune recovery uveitis: pathogenesis, clinical symptoms, and treatment. Mediators Inflamm. 2014:1–10
Rodrigues Alves N, Barão C, Mota C, Costa L, Proença RP (2024) Immune recovery uveitis: a focus review. Graefes Arch Clin Exp Ophthalmol. 262(8):2703–12